U.S. markets close in 1 hour 56 minutes

Alnylam Pharmaceuticals Inc (DUL.BE)

Berlin - Berlin Delayed Price. Currency in EUR
174.08+0.84 (+0.48%)
As of 06:35PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close173.24
Bid173.28 x N/A
Ask174.80 x N/A
Day's Range172.28 - 174.78
52 Week Range113.36 - 230.45
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateApr 26, 2023 - May 01, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DUL.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • InvestorPlace

      3 Growth Stocks That Could Disrupt the Healthcare Industry

      Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health

    • CNW Group

      Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

      Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.

    • Business Wire

      Alnylam Announces Appointment of Peter Kellogg to Board of Directors

      CAMBRIDGE, Mass., March 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.